world-biomarkers-pharma-biotech-2017-tracks

22 / 28

Notes:
Volume10, Issue 12 (Suppl) J Proteomics Bioinform, an open access journal
ISSN: 0974-276X
Page 50
conferenceseries.com
World Biomarkers & Pharma Biotech 2017
December 07-09, 2017
December 07-09, 2017 | Madrid, Spain
&
20th International Conference on
PHARMACEUTICAL BIOTECHNOLOGY
9th WORLD BIOMARKERS CONGRESS
JOINT EVENT ON
RhoGDI3, is this small molecular regulator key orchestring the movement and tumormass in PDAC?
Mercedes Piedad de León Bautista1,2,3, María del Carmen Cárdenas Aguayo4, Daniel Marrero3,5, Mauricio Salcedo5, Lorena Gorgonio Eusebio 3, Emma
Vélez Uriza3, Miguel Vargas3 and Rocío Thompson Bonilla 2
1Central ADN, Mexico
2ISSSTE, Mexico
3CINVESTAV-IPN, Mexico
4Facultad de Medicina, UNAM, Mexico
5XXI Century National Medical Center, Mexico
Pancreatic ductal adenocarcinoma (PDAC) is a complex pathology with poor prognosis. Efforts have been focused on
understanding the role of RhoGDI's in PDAC, in particular, RhoGDI1 and RhoGDI2. However, the role of RhoGDI3 has neither
been studied in relation to cancer nor to PDAC. Our group have characterized the expression and functionality of RhoGDI3 and its
target GTPases, RhoG and RhoB, in pancreatic cell lines and compared it to human tissue. Through immunofluorescences, pull down
assays, subcellular fractionation and immunohistochemistry, we found a reduction in RhoGDI3 expression in PDAC late stages, and
this reduction correlates with tumor progression and aggressiveness. Despite the reduction in the expression of RhoGDI3 in PDAC,
we found that RhoB was under expressed while RhoG was over expressed, suggesting that cancerous cells keep their capacity to
activate this pathway, thus these cells may be eager to the stimuli needed to proliferate and become invasive. Surprisingly, we found
nuclear localization of RhoGDI3 in non-cancerous pancreatic cell line and normal pancreatic tissue biopsies, which could open the
possibility of novel nuclear functions for this protein, impacting gene expression regulation and cellular homeostasis. To elucidate
the possible functions of RhoGDI3 in cancer maintenance, the overexpression assays have demonstrated that increased RhoGDI3
protein increases proliferation rate; besides, the xenograft tumor was smaller compared to the mock, suggesting and predicting that
overexpression of RhoGDI3 is an important molecule to constrain the tumoral volume. In conclusion, RhoGDI3 protein decreases
the malignant behavior in PDAC.
Biography
Mercedes Piedad de León Bautista has completed her Bachelor’s Degree from UPAEP University School of Medicine, and an MSc and PhD from CINVESTAV-IPN
in the Dept. of Molecular Biomedicine. She is the Medical Director and Laboratory Chief of Central ADN, a molecular laboratory focusing on human health and
translational medicine. She has been working with PDAC and, nowadays, her biomedical efforts are based on molecular platforms to find new markers in cancer
and hereditary diseases.
Mercedes Piedad de León Bautista et al., J Proteomics Bioinform 2017, 10:12(Suppl)
DOI: 10.4172/0974-276X-C1-109